Source disclosure: February 13, 2026
PhoenixBio Co., Ltd. [6190.T]
TOKYO, Feb 19 (Pulse News Wire) – Phoenixbio Co., Ltd. (6190.T) reported consolidated results for Q3 FY2026 (ending March 2026).
20 billion (+5.0% YoY).
20 billion with an equity ratio of 68.4%.
For the next fiscal year, the company forecasts 64 billion (+6.4%).
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms •Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥1,200M | +5.0% |
| Operating profit | ¥68M | +98.0% |
| Net profit | n/a | n/a |
Next period forecast
Revenue
¥1,640M
+6.4%Op. profit
¥109M
+116.0%Source: TDNet filing · Figures in millions of yen
💬 Help us improve translation quality
Notice any errors in this article? Let us know with one click.